Zacks: Brokerages Anticipate Motus GI Holdings Inc (NASDAQ:MOTS) Will Post Quarterly Sales of $280,000.00

Wall Street analysts expect Motus GI Holdings Inc (NASDAQ:MOTS) to report sales of $280,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Motus GI’s earnings, with the lowest sales estimate coming in at $250,000.00 and the highest estimate coming in at $300,000.00. The business is expected to report its next quarterly earnings report on Wednesday, March 25th.

On average, analysts expect that Motus GI will report full year sales of $280,000.00 for the current fiscal year, with estimates ranging from $260,000.00 to $300,000.00. For the next fiscal year, analysts forecast that the business will report sales of $8.30 million, with estimates ranging from $6.11 million to $10.50 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Motus GI.

Motus GI (NASDAQ:MOTS) last posted its quarterly earnings data on Thursday, November 14th. The company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.07.

Several equities analysts recently weighed in on MOTS shares. Dougherty & Co set a $7.00 target price on Motus GI and gave the company a “buy” rating in a research report on Thursday, September 26th. Zacks Investment Research upgraded Motus GI from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a report on Wednesday, November 20th.

In other Motus GI news, Director Gary E. Jacobs bought 17,000 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was acquired at an average cost of $1.54 per share, with a total value of $26,180.00. Following the completion of the purchase, the director now directly owns 9,100 shares in the company, valued at $14,014. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 18.14% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. CVI Holdings LLC purchased a new position in Motus GI in the 2nd quarter worth approximately $42,000. Northern Trust Corp bought a new stake in Motus GI in the second quarter worth $52,000. Morgan Stanley boosted its holdings in Motus GI by 1,333.3% in the second quarter. Morgan Stanley now owns 30,100 shares of the company’s stock worth $91,000 after acquiring an additional 28,000 shares in the last quarter. Stonepine Capital Management LLC bought a new stake in Motus GI in the second quarter worth $107,000. Finally, BlackRock Inc. boosted its holdings in Motus GI by 1,004.4% in the second quarter. BlackRock Inc. now owns 69,889 shares of the company’s stock worth $212,000 after acquiring an additional 63,561 shares in the last quarter. Institutional investors and hedge funds own 43.30% of the company’s stock.

NASDAQ MOTS traded down $0.15 on Thursday, hitting $2.30. 148,151 shares of the company traded hands, compared to its average volume of 101,632. The company has a market capitalization of $70.55 million, a price-to-earnings ratio of -1.87 and a beta of 1.52. The company has a current ratio of 7.80, a quick ratio of 7.59 and a debt-to-equity ratio of 0.03. The business’s 50 day moving average price is $1.80 and its 200-day moving average price is $2.53. Motus GI has a 52-week low of $1.43 and a 52-week high of $4.99.

About Motus GI

Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.

See Also: What are economic reports?

Get a free copy of the Zacks research report on Motus GI (MOTS)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Motus GI (NASDAQ:MOTS)

Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with's FREE daily email newsletter.